Hematological Malignancies

non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-Line Indolent trial. Morschhauser F, et al J Clin Oncol. 2013 ;31(16):1977-83.

100

The 7-year PFS among patients with a CR/CRu after induction was 36% in the control arm compared with 57% in the 90 Y-ibritumomab arm

HR = 1.72 (95% CI: 1.18 – 2.50); P = 0.004

75

90 Y-ibritumomab: n = 107 Median PFS: > 107 mo

50

Control: n = 108 Median PFS: 32.4 mo

25

N F

Cumulative Percentage 90 Y-ibritumomab Control

107 108

47 67

0

21

42

63

84

0

PFS From Time of Randomization (months)

At risk:

90 Y-ibritumomab Control

107 108

79 65

60 49

53 39

16 11